Study guide
A1C and Ketone Monitoring
CDCES Certified Diabetes Care and Education Specialist
Track your progress as you read
Finished sections get a check mark.
1 Introduction & the CDCES Exam
About the CDCES Credential & Current Exam Facts The July 2024 Exam Content Outline & Domain Weights The ADCES7 Self-Care Behaviors Framework
2 Pathophysiology, Classification & Diagnosis
Normal Glucose Regulation and the Pathophysiology of T1DM and T2DM Classification and Diagnostic Criteria Risk Factors and Primary Prevention Treatment Goals and Glycemic Targets
3 Assessment: History, Physical & Data
Health History & Diabetes-Specific Physical Assessment Interpreting Diabetes Measures & Laboratory Data Social Determinants of Health & Psychosocial Wellbeing
4 Assessing Self-Management & Learning
Assessing Self-Management Behaviors & Knowledge Assessing Technology Use, Problem-Solving & Risk-Reduction Behaviors Assessing Learning: Goals, Readiness to Change & Literacy Learning Considerations & Barriers
5 Developing the Education & Care Plan
Developing the Individualized Education/Care Plan Instructional Methods & Person-Centered Teaching Strategies SMART Goals, Behavior-Change Theory & Motivational Interviewing
6 Nutrition Therapy
Nutrition Recommendations & Eating Patterns Carbohydrate Counting & Insulin-Food Timing Fats, Protein, Alcohol & Dietary Supplements Food Labels, Weight Management & Special Nutrition Considerations
7 Physical Activity
Physical Activity Recommendations, Benefits, Challenges & Safety Activity Planning with FITT and Adjusting for Planned & Unplanned Activity
8 Pharmacologic Therapy
Insulin — Types, Pharmacokinetics & Delivery Systems Non-Insulin Glucose-Lowering Agents Guideline-Based Medication Selection Medication Titration & Immunizations for People with Diabetes
9 Monitoring
Glucose Monitoring: SMBG, CGM & Time in Range A1C and Ketone Monitoring Cardiometabolic and Organ System Monitoring
10 Acute Complications
Hypoglycemia Hyperglycemia, DKA, and HHS
11 Chronic Complications
Screening Schedules and Microvascular Disease Macrovascular Disease and Lower-Extremity Foot Care Infections, Dental Disease, Sexual Dysfunction, and Other Comorbidities
12 Special Situations & Populations
Sick-Day Management, Surgery, Travel & Emergency Preparedness Special Populations Across the Lifespan Preconception, Pregnancy, Postpartum & Gestational Diabetes Daily Living, Psychosocial Wellbeing & Safety
13 Evaluation & Documentation
Evaluating Intervention Effectiveness & Outcomes Documentation, Plan Revision & Referral
14 Standards, Guidelines & Professional Practice
National Standards for DSMES and the National DPP Applying Evidence-Based Practice Guidelines Population Health, Health Equity & Advocacy
A1C and Ketone Monitoring
Key Takeaways Explain This Topic AI
ADA recommends A1C testing at least twice a year for people at glycemic goal and every 3 months for those not at goal or after a therapy change.
Pregnancy, hemolytic anemia, chronic kidney disease, and erythropoietin therapy can all falsely lower A1C by shortening red blood cell lifespan.
Blood ketone testing measures beta-hydroxybutyrate (BHB) and is preferred over urine ketone testing because it reflects real-time status and treatment response.
ADA sick-day guidance recommends checking ketones when blood glucose is persistently above 240 mg/dL, roughly every 4-6 hours during illness.
A blood BHB level above 3.0 mmol/L indicates high likelihood of diabetic ketoacidosis and requires immediate emergency care.
Last updated: July 2026
A1C: Uses and Frequency
A1C (glycated hemoglobin) measures the fraction of hemoglobin bound to glucose and reflects average glycemia over roughly the preceding 2-3 months , weighted more heavily toward the most recent 30 days — about half of the result reflects the most recent month. A1C remains the primary tool for diagnosing diabetes and prediabetes (Chapter 2) and for tracking the long-term glycemic control most closely tied to microvascular risk reduction.
ADA Standards of Care recommend obtaining A1C at least twice a year in people who are meeting glycemic goals with stable therapy, and every 3 months in people who are not at goal, have had a recent medication or regimen change, or have experienced a change in health status such as illness, pregnancy, or new hypoglycemia. The CDCES pairs A1C's long-term trend with CGM-based Time in Range and GMI (Section 9.1) for a complete glycemic picture at each visit, since no single metric tells the whole story.
Not all A1C tests are equivalent. Laboratory-based A1C run on an NGSP-certified, DCCT-aligned assay is the reference standard; point-of-care (POC) A1C meters used for same-visit results are convenient for shared decision-making but are not accurate enough to diagnose diabetes and should be confirmed with a laboratory assay when used for that purpose. The CDCES should know which assay type produced a given result before comparing serial values, since switching between POC and laboratory methods can create an apparent trend that is really assay variability rather than a true change in glycemia.
A1C Limitations
Because A1C is a hemoglobin-glycation assay, anything that alters red blood cell lifespan or hemoglobin structure distorts the result independent of true average glucose:
Hemoglobinopathies (sickle cell trait or disease, HbC, HbE, and other structural variants) can produce falsely low or falsely high A1C depending on the assay method; a hemoglobin-variant-insensitive assay, or an alternative marker, should be used when a variant is known.
Conditions with shortened red blood cell lifespan — hemolytic anemia, recent significant blood loss, chronic kidney disease/end-stage renal disease, and erythropoietin therapy — falsely lower A1C because circulating glucose has less time to bind hemoglobin.
Iron-deficiency anemia and vitamin B12 or folate deficiency , which extend red blood cell lifespan, can falsely raise A1C.
Pregnancy lowers A1C independent of glycemic control (expanded red blood cell turnover and blood volume), so A1C alone under-detects hyperglycemia in pregnancy; CGM-based Time in Range is the preferred metric (Chapter 12).
When A1C and SMBG/CGM data disagree, the CDCES should suspect one of these discordance causes rather than assume inaccurate self-monitoring, and may substitute fructosamine (reflects roughly the prior 2-3 weeks) or CGM-derived GMI and Time in Range as the working glycemic metric.
Ketone Monitoring
Ketones — acetoacetate, acetone, and beta-hydroxybutyrate (BHB) — accumulate when the body burns fat for fuel because of absolute or relative insulin deficiency, the physiologic root of diabetic ketoacidosis (DKA, Chapter 10). Two testing methods exist:
Method What It Measures Key Limitation
Urine ketone strips Acetoacetate (semi-quantitative) Lags true ketone status; can stay positive after resolution or miss an early rise
Blood ketone meter Beta-hydroxybutyrate, BHB (quantitative, mmol/L) Preferred by ADA — real-time, more sensitive and specific, tracks treatment response faster
When to test: during any acute illness in insulin-treated diabetes, whenever blood glucose is persistently above 240 mg/dL , during pregnancy with type 1 diabetes (routine morning checks, especially with reduced caloric intake), and with any symptom suggestive of DKA — nausea, vomiting, abdominal pain, or fruity-smelling breath. ADA sick-day guidance recommends checking ketones every 4-6 hours while illness and elevated glucose persist. For people using urine strips, first-morning or symptomatic-period samples are most informative, and strips should be checked against their expiration date, since degraded strips under-read.
Ketone testing carries extra urgency for people using insulin pump therapy. Because pumps deliver only rapid-acting insulin with no long-acting depot in the body, an interrupted infusion — a dislodged cannula, occlusion, empty reservoir, or mechanical failure — can produce insulin deficiency and rising ketones within a few hours, far faster than for someone using long-acting basal injections. The CDCES teaches pump users to check ketones for any unexplained hyperglycemia regardless of the 240 mg/dL threshold, to keep backup injectable insulin available, and to switch to injections while troubleshooting a suspected pump malfunction.
Pregnancy also accelerates ketosis: overnight fasting alone can produce measurable ketones in a pregnant woman with type 1 diabetes even without hyperglycemia, so routine morning testing — not only illness-triggered testing — is standard prenatal self-care (Chapter 12).
Interpreting blood BHB:
Below 0.6 mmol/L — normal
0.6-1.5 mmol/L — mild-to-moderate ketosis; follow the sick-day correction-dose plan, increase fluids, and recheck
- 1.6-3.0 mmol/L — high risk; contact the diabetes care team
- Above 3.0 mmol/L — high likelihood of DKA; seek emergency care immediately
The CDCES teaches core sick-day rules alongside ketone testing: never stop basal or background insulin, increase monitoring frequency, maintain hydration, use a pre-established correction-dose plan for hyperglycemia with ketones, and know the specific glucose and ketone thresholds that require calling the provider or going to the emergency department — expanded further in Chapter 12's sick-day management section.